Loprox is a drug owned by Bausch Health Us Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 16, 2017. Details of Loprox's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8227490 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Sep, 2017
(7 years ago) |
Expired
|
| US7981909 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Sep, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Loprox's patents.
Latest Legal Activities on Loprox's Patents
Given below is the list of recent legal activities going on the following patents of Loprox.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 31 Aug, 2020 | US8227490 |
| Maintenance Fee Reminder Mailed Critical | 16 Mar, 2020 | US8227490 |
| Expire Patent Critical | 26 Aug, 2019 | US7981909 |
| Maintenance Fee Reminder Mailed Critical | 11 Mar, 2019 | US7981909 |
| Recordation of Patent Grant Mailed Critical | 24 Jul, 2012 | US8227490 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Jul, 2012 | US8227490 |
| Email Notification Critical | 05 Jul, 2012 | US8227490 |
| Issue Notification Mailed Critical | 04 Jul, 2012 | US8227490 |
| Dispatch to FDC | 27 Jun, 2012 | US8227490 |
| Application Is Considered Ready for Issue Critical | 25 Jun, 2012 | US8227490 |
US patents provide insights into the exclusivity only within the United States, but Loprox is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Loprox's family patents as well as insights into ongoing legal events on those patents.
Loprox's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Loprox's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 16, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Loprox Generic API suppliers:
Ciclopirox is the generic name for the brand Loprox. 17 different companies have already filed for the generic of Loprox, with Fougera Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Loprox's generic
Alternative Brands for Loprox
Loprox which is used for managing seborrheic dermatitis on the skin and scalp., has several other brand drugs using the same active ingredient (Ciclopirox). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alvogen |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ciclopirox, Loprox's active ingredient. Check the complete list of approved generic manufacturers for Loprox
About Loprox
Loprox is a drug owned by Bausch Health Us Llc. It is used for managing seborrheic dermatitis on the skin and scalp. Loprox uses Ciclopirox as an active ingredient. Loprox was launched by Bausch in 2003.
Approval Date:
Loprox was approved by FDA for market use on 28 February, 2003.
Active Ingredient:
Loprox uses Ciclopirox as the active ingredient. Check out other Drugs and Companies using Ciclopirox ingredient
Treatment:
Loprox is used for managing seborrheic dermatitis on the skin and scalp.
Dosage:
Loprox is available in shampoo form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | SHAMPOO | Prescription | TOPICAL |